SCRI Oncology Partners

What SCRI Oncology Partners does

SCRI Oncology Partners is a privately held, community-based cancer treatment center headquartered in Nashville, Tennessee, with 25 employees and a medical staff of 25+ physicians and advanced practice providers. The practice is affiliated with the Sarah Cannon Research Institute (SCRI) and operates as a member of The US Oncology Network, giving it access to one of the largest community oncology infrastructures in the United States. It is the only oncology provider in the Nashville market offering Phase I through Phase IV clinical trials, and its providers have collectively contributed to over 170 research journals, signaling active participation in oncology research and trial enrollment across multiple tumor types including breast, hematologic, thoracic, and gastrointestinal cancers.

On September 24, 2025, the practice launched a dedicated Center for Breast Health and High-Risk Clinic, formalizing breast cancer screening, treatment, and risk assessment under a single service line. The practice has also recently expanded its medical staff with additions in hematology and breast surgical oncology and has integrated digital patient-engagement (Navigating Care) and revenue-cycle (GoToBilling) platforms to support operational scaling.

The business model is a fee-for-service clinical-care model: revenue is generated from reimbursement for office visits, infusion services, imaging, surgical procedures, and clinical trial enrollment, billed to commercial insurance, Medicare, Medicaid, and self-pay patients across Middle Tennessee and adjacent states. The go-to-market motion is primarily physician referral–driven, supplemented by community outreach and event-based patient engagement, and is reinforced by the brand recognition of the Sarah Cannon and US Oncology Network affiliations.

Name

SCRI Oncology Partners

Legal name

SCRI Oncology Partners

Website

https://cancercarescri.com

Company type

Private

Operating status

Operating

Short description

SCRI Oncology Partners is a private, Nashville-based community cancer treatment center and the only Nashville provider offering Phase I–IV clinical trials, serving patients across Middle Tennessee through its affiliation with Sarah Cannon Research Institute and The US Oncology Network.

Ownership category

akta.pro rank

Product category

Oncology Care Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industries

Surgical Oncology (HLAKAFAG), Gynecologic Oncology (HLAKAFAF)

Keywords

• Oncology care services
• Cancer treatment center
• Clinical trials
• Precision oncology
• Immunotherapy treatments

Headquarters

HQ city

Nashville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. Oncology Care Services: Direct patient care services including chemotherapy, immunotherapy, targeted therapy, hormone therapy, radiation therapy, and surgical services for cancer treatment. Revenue generated through medical services billed to patients and insurance providers.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

SCRI Oncology Partners is a Nashville-based cancer treatment center delivering comprehensive oncology care including chemotherapy, immunotherapy, targeted therapy, hormone therapy, bispecific therapy, radiation therapy, and breast cancer surgery. The center offers diagnostic services such as next-generation sequencing (NGS) for biomarker testing and genetic testing, alongside supportive services including palliative care, financial counseling, and survivorship programs. Through affiliation with Sarah Cannon Research Institute, it provides access to Phase I-IV clinical trials.

Product overview

SCRI Oncology Partners is a Nashville-based cancer treatment center offering a unified platform of integrated oncology services. The core treatment portfolio includes chemotherapy, immunotherapy, targeted therapy, hormone therapy, bispecific therapy, and radiation therapy, complemented by diagnostic services such as next-generation sequencing (NGS) for biomarker testing and genetic testing. The organization operates specialty centers including the Center for Breast Health with High-Risk Breast Clinic, and provides supportive care services including palliative care, financial counseling, survivorship programs, and caregiver resources. Through its affiliation with Sarah Cannon Research Institute, SCRI Oncology Partners offers access to Phase I-IV clinical trials—the only organization in Nashville providing all phases of clinical trials. The unified offering combines cutting-edge treatments with compassionate, personalized patient care.

Differentiator

Problem solved

Functional benefit

Brands

• Center for Breast Health: A specialized center focused on breast health, launched in September 2025, offering comprehensive breast cancer care and a High-Risk Clinic.

Products and services

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Hormone Therapy
• Bispecific Therapy
• Radiation Therapy
• Breast Cancer Surgery
• Next-Generation Sequencing (NGS)
• Genetic Testing
• Clinical Trials
• Center for Breast Health
• High-Risk Breast Clinic
• Palliative Care Services
• Financial Counseling
• Survivorship Program
• Second Opinion Services

Quantifiable outcome

• Only Phase I-IV clinical trial provider in Nashville
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Sarah Cannon Research Institute (SCRI)coreStrategic or Co-development PartnerSCRI Oncology Partners conducts clinical trials through affiliation with Sarah Cannon Research Institute, one of the world's leading oncology research organizations. Since its inception more than 30 years ago, SCRI has contributed to pivotal research that has helped advance the majority of new cancer therapies approved by the U.S. Food and Drug Administration (FDA) today. This partnership provides patients direct access to the latest clinical trials and innovative treatments.
• The US Oncology NetworkcoreStrategic or Co-development PartnerSCRI Oncology is a member of The US Oncology Network, a national network of over 2,600 independent physicians dedicated to providing collaborative localized care to enable better support for cancer patients. Led by physicians, the network focuses on using the latest technology and best practices to ensure integrated care is available and accessible to more people in their local communities, working with physicians, payers, hospitals and academic institutions across the United States.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Tennessee Oncology: Largest independent community oncology practice in Tennessee, headquartered in Nashville; directly competes with SCRI Oncology Partners for the same patient population, referring physicians, and clinical trial slots across Middle Tennessee.
• Florida Cancer Specialists & Research Institute: Large community oncology practice with deep Phase I-IV clinical trial infrastructure and Sarah Cannon/US Oncology Network affiliations; operates with a similar scale, multispecialty physician mix, and community-based trial model outside of Florida.
• OneOncology: Network of independent community oncology practices; a parallel platform to US Oncology Network that competes for the same independent practice acquisition and partnership pipeline.
• START (Clinical Research): Global Phase I-focused oncology research network; competes for early-phase drug development trial placements and biopharma sponsor relationships with the same investigator pool.
• Maryland Oncology Hematology: US Oncology Network-affiliated community oncology practice operating under the same parent network and partnership template as SCRI Oncology Partners.
• Willamette Valley Cancer Institute: US Oncology Network-affiliated community oncology practice; closely comparable operating model with multi-specialty medical oncology, clinical trials, and supportive care services.

Broad incumbents

• Sarah Cannon Research Institute: One of the world's leading oncology research organizations and the research partner of SCRI Oncology Partners; conducts Phase I-IV trials across a national network and is the upstream provider of trial access that anchors SCRI Oncology Partners' differentiation.
• City of Hope: Large NCI-designated cancer center expanding into community oncology through acquisitions; represents the academic-system capital that may eventually compete for community trial sites in the Southeast.
• MD Anderson Cancer Center: Premier global academic cancer center; competes for the highest-acuity second opinions, complex trial patients, and sets the clinical benchmark that community research practices are measured against.

Regional players

• Vanderbilt-Ingram Cancer Center: NCI-designated academic cancer center in Nashville; competes for high-acuity and complex trial patients, second opinions, and specialist referrals in the same primary geography.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/SCRIOncology/status/1842626756546875781
• YouTubeyoutube.com/@SCRIOncologyPartners
• Facebookfacebook.com/SCRIOncologyPartners/?_rdr
• LinkedInlinkedin.com/company/scri-oncology-partners

Revenue estimate

Valuation estimate

Number of profiles

Profiles27 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SCRI Oncology Partners